Tinnitus in patients on therapy with proton pump inhibitors (PPI) and in PPI non-users

被引:2
|
作者
Pirodda, Antonio [1 ]
Raimondi, Maria Chiara [1 ]
Cicero, Arrigo Francesco Giuseppe [2 ]
Rosticci, Martina [2 ]
Rinaldi, Elisa Rebecca [2 ]
Bellacosa, Lara [2 ]
Stanghellini, Vincenzo [2 ]
Borghi, Claudio [2 ]
机构
[1] Univ Bologna, Dept Expt Diagnost & Specialty Med, Via Massarenti,9, I-40138 Bologna, Italy
[2] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy
关键词
proton pump inhibitors; inner ear disorders;
D O I
10.3109/21695717.2014.902554
中图分类号
R36 [病理学]; R76 [耳鼻咽喉科学];
学科分类号
100104 ; 100213 ;
摘要
Objective: We wished to observe the prevalence of tinnitus in subjects on therapy with proton pump inhibitors (PPI). A possible favourable effect of the commercially available proton pump inhibitors (PPI) on inner ear disorders was recently outlined. In order to investigate this possibility the prevalence of tinnitus (an indicator of labyrinthine sufferance in general terms) among PPI users and non-users was analysed. Study design: An observational study on the prevalence of tinnitus among PPI users and non-users was carried out. Between June 2012 and March 2013 a cohort of consecutive patients who were referred to S. Orsola-Malpighi University Hospital of Bologna for various non-audiological disorders was included in the study. Each patient was instructed to complete an anonymous validated questionnaire on hearing problems. The Ethics Committee of S. Orsola Malpighi Hospital had been informed about collection of the data. Results: In the age class 60-69 years there was a statistically significant lower prevalence of non-specified tinnitus in PPI users, compared to non-users. Conclusion: Even if a favourable effect on this symptom derived from the treatment of gastroesophageal reflux cannot be excluded, a direct regulatory effect on inner ear homeostasis, through the action of PPI on the gastric type proton pump of the inner ear, cannot be ruled out. Another possible effect could depend upon vasomotor activity enabling better peripheral perfusion without significantly modifying blood pressure values, thus contributing to the stabilization of inner ear oxygenation. Additionally, a certain degree of anti-inflammatory effect could yield another kind of non-specific favourable influx. In conclusion, even if the supposed benefit deriving from the use of PPI in treating inner ear affections of unknown origin is still unclear with regard to its significance and limits, the reported results demonstrate that longitudinal studies could be useful in order to verify the possibility of a new therapeutic perspective.
引用
收藏
页码:84 / 87
页数:4
相关论文
共 50 条
  • [31] Helicobacter pylori Therapy in Children: A Focus on Proton Pump Inhibitors
    Chiesa, Claudio
    Anania, Caterina
    Pacifico, Lucia
    Olivero, Giuseppe
    Osborn, John F.
    CHEMOTHERAPY, 2011, 57 (01) : 85 - 93
  • [32] Hypomagnesemia in Hemodialysis Patients:Role of Proton Pump Inhibitors
    Alhosaini, Mohamad
    Walter, James S.
    Singh, Sanjay
    Dieter, Robert S.
    Hsieh, Annming
    Leehey, David J.
    AMERICAN JOURNAL OF NEPHROLOGY, 2014, 39 (03) : 204 - 209
  • [33] How useful are proton-pump inhibitors for diagnosis and therapy of patients with noncardiac chest pain?
    Matthews, PJ
    Aziz, Q
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2005, 2 (11): : 506 - 507
  • [34] Reduction of the long-term use of proton pump inhibitors by a patient-oriented electronic decision support tool (arriba-PPI): study protocol for a randomized controlled trial
    Anja Rieckert
    Annette Becker
    Norbert Donner-Banzhof
    Annika Viniol
    Bettina Bücker
    Stefan Wilm
    Andreas Sönnichsen
    Anne Barzel
    Trials, 20
  • [35] A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens
    Chevalier, Rachel
    Attard, Thomas
    Van Driest, Sara L.
    Shakhnovich, Valentina
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (02) : 53 - 56
  • [36] Reduction of the long-term use of proton pump inhibitors by a patient-oriented electronic decision support tool (arriba-PPI): study protocol for a randomized controlled trial
    Rieckert, Anja
    Becker, Annette
    Donner-Banzhof, Norbert
    Viniol, Annika
    Buecker, Bettina
    Wilm, Stefan
    Soennichsen, Andreas
    Barzel, Anne
    TRIALS, 2019, 20 (01)
  • [37] Risk of dementia in elderly patients with the use of proton pump inhibitors
    Britta Haenisch
    Klaus von Holt
    Birgitt Wiese
    Jana Prokein
    Carolin Lange
    Annette Ernst
    Christian Brettschneider
    Hans-Helmut König
    Jochen Werle
    Siegfried Weyerer
    Melanie Luppa
    Steffi G. Riedel-Heller
    Angela Fuchs
    Michael Pentzek
    Dagmar Weeg
    Horst Bickel
    Karl Broich
    Frank Jessen
    Wolfgang Maier
    Martin Scherer
    European Archives of Psychiatry and Clinical Neuroscience, 2015, 265 : 419 - 428
  • [38] The Safety of Proton Pump Inhibitors and Clopidogrel in Patients After Stroke
    Juurlink, David N.
    Gomes, Tara
    Mamdani, Muhammad M.
    Gladstone, David J.
    Kapral, Moira K.
    STROKE, 2011, 42 (01) : 128 - 132
  • [39] Metformin plus proton pump inhibitors therapy: the cobalamin deficiency challenge
    Purchiaroni, F.
    Galli, G.
    Annibale, B.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2015, 19 (13) : 2501 - 2502
  • [40] Hypocalcemia after parathyroidectomy in patients taking proton pump inhibitors
    Lorenz, Jeffrey
    Goldenberg, David
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2023, 44 (02)